Migra Therapeutics, founded by Drs. Lily Yang and Lei Zhu in Atlanta, Georgia, is a biopharmaceutical company dedicated to the clinical translation and commercialization of innovative drug delivery systems. Their core mission is to develop and implement nanotechnology-based therapies to combat cancer more effectively. The company focuses on creating targeted nanoparticles that can penetrate dense cancer cell barriers, such as stroma in pancreatic and breast cancers, to deliver chemotherapy drugs and therapeutic antibodies more efficiently.

Notable figures affiliated with Migra Therapeutics include its founders, Drs. Lily Yang and Lei Zhu, who are also researchers at Emory University. The company has made significant strides in the field of targeted drug delivery, leveraging their academic research to create practical medical solutions. Their innovative approach has the potential to revolutionize cancer treatment by improving drug efficacy and reducing side effects, thereby making a substantial impact on patient outcomes.